HDAC9 and glioblastoma: Another class of drugs scoring highly against the AM630 profile are the HDAC inhibitors: scriptaid, vorinostat and trichostatin A. HDAC inhibition has also been proposed as an intervention in GBM [36] with vorinostat reaching phase II clinical trials for GBM [37] and scriptaid inducing glioma cell apoptosis [38].